



SCOTT-EDIL PHARMACIA LTD.

56, EPIP, Phase-I Jharmajri, Baddi,
Distt. Solan (H.P.), 173205 INDIA

Summary of Product Characteristics (SPC)

1. Name of the medicinal product

Nosore (Choline Salicylate, Lidocaine HCL & Benzalkonium Chloride Gel)

1.1 International Non-Proprietary Name (INN)

Choline Salicylate Solution BP

Lidocaine Hydrochloride BP

1.2 Strength

10g

1.3 Pharmaceutical form

Cream for topical application

2. Qualitative and quantitative composition

Choline Salicylate Solution BP

Eq. to Choline Salicylate 8.7% w/w

Lidocaine Hydrochloride BP 2.0% w/w

Benzalkonium Chloride Solution BP 0.01%w/w

In a pleasant flavoured gel base q.s

3. Pharmaceutical form

Cream for topical application.

Transparent, clear, jelly mass filled in printed laminated tube.

4. Clinical particulars

4.1 Therapeutic indications

For the relief of pain and discomfort of common mouth ulcers, cold sores, denture sore spots, infant teething and mouth ulcers, and sore spots due to orthodontic devices in children.

To aid healing of sore spots and ulcers due to dentures in adults and orthodontic devices in children.

4.2 Posology and method of administration

By topical application to the oral mucosa.

Adults: Using a clean finger, massage approximately one centimetre of the gel onto the sore area, not more than once every 3 hours.

Children (from four months): Using a clean finger, massage a pea size amount of gel onto the sore area, not more than once every 3 hours. Do not apply more than six doses in any 24 hour period. Not suitable for infants under four months.



SCOTT-EDIL PHARMACIA LTD.

56, EPIP, Phase-I Jharmajri, Baddi,
Distt. Solan (H.P.), 173205 INDIA

Do not exceed the stated dose.

Orthodontic devices: Apply to the sore area as described above, not more than once every 3 hours.

Denture irritation: Apply and leave at least 30 minutes before re-insertion of the dentures. Do not apply this product directly to the dentures.

If symptoms do not improve after 7 days seek medical advice.

Older people:

There is no indication that dosage need be modified in the elderly.

Method of administration:

Topical Cream (External Preparation)

4.3 Contraindications

Not to be used in infants under four months.

Hypersensitivity to choline salicylate, cetalkonium chloride or to any of the excipients in the product.

Not to be used in patients with hypersensitivity to salicylates, aspirin or other NSAIDs, to cetylpyrдинium or to any of the excipients.

Not to be used in patients with active or a history of recurrent peptic ulceration.

Do not use in patients currently suffering from viral illnesses such as varicella (chicken pox) or influenza infection particularly in children and adolescents under 16 years of age due to the risk of precipitating Reye's syndrome in this patient population.

4.4 Special warnings and precautions for use

The recommended dose and frequency should not be exceeded especially in children under 16 years due to risk of Reye's syndrome and salicylate poisoning.

This product contains salicylate and should not be used with aspirin or other salicylates except under the direction of a doctor or dentist

This medicine contains 46.83 mg of alcohol (ethanol) in each dose. The amount in each dose of this medicine is equivalent to less than 2 ml beer or 1 ml of wine.

The small amount of alcohol in this medicine will not have any noticeable effects.

It may cause burning sensation on damaged skin.

This medicine contains less than 1 mmol sodium (23 mg) in each dose, that is to say essentially 'sodium-free'.

This medicine contains fragrance with d-Limonene, anisyl alcohol and linalool.

d-Limonene, anisyl alcohol and linalool may cause allergic reactions.

In addition to allergic reactions in sensitised patients, nonsensitised patients may become sensitised.

Contact your doctor or dentist if you have an active or recurring stomach ulcer.

Contact your doctor or dentist if you are currently suffering from a viral infection such as varicella (chicken pox) or influenza infection.

Consult your doctor if you are pregnant or breastfeeding.

If there is no improvement after 7 days or there is aggravation of the condition, the doctor or dentist should be consulted.

4.5 Interaction with other medicinal products and other forms of interaction

Salicylates may enhance the effect of anticoagulants and inhibit the action of uricosurics.

4.6 Pregnancy and lactation



SCOTT-EDIL PHARMACIA LTD.

56, EPIP, Phase-I Jharmajri, Baddi,
Distt. Solan (H.P.), 173205 INDIA

Pregnancy:

There is clinical evidence of the safety of salicylates in pregnancy, but they may prolong bleeding and contribute to maternal and neonatal bleeding, and are best avoided at term.

Breast-feeding:

Salicylates are excreted at low concentrations in breast milk, and may adversely affect the infant in very rare cases.

Fertility:

There is no information on the effects of topical oral choline salicylate and fertility.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

The list of the following adverse effects relates to those experienced with topical oral salicylates at OTC doses, in short-term use. In the treatment of chronic conditions, under long-term treatment, additional adverse effects may occur.

Adverse events which have been associated with salicylates are given below, listed by system organ class and frequency. Frequencies are defined as: very common ($\geq 1/10$), common ($\geq 1/100$ and $< 1/10$), uncommon ($\geq 1/1000$ and $< 1/100$), rare ($\geq 1/10,000$ and $< 1/1000$), very rare ($< 1/10,000$); Not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.

There have been post-marketing reports of cases of suspected Reyes syndrome and possible salicylate toxicity in children who had a history of use of choline salicylate gels but causality has not been established.

System Organ Class	Frequency	Adverse Events
Immune system disorders	Not known	Hypersensitivity
Nervous system disorders	Not known	Paraesthesia (transient numbing and stinging)
Respiratory, thoracic and mediastinal disorders	Not known	Bronchospasm and asthma
Gastrointestinal disorders	Not known	Stomatitis

Description of Selected Adverse Reactions

Salicylates may precipitate bronchospasm and induce asthma attacks in susceptible patients. They can cause stomatitis, burns and allergic reactions.

4.9 Overdose

Dealing with the potential for toxicity with local application, especially in infants:

As choline salicylate is absorbed across the buccal mucosa, the possibility exists for toxicity, especially in infants hence the need for caution not to exceed the stated dose and monitor for any signs of suggested salicylism.



SCOTT-EDIL PHARMACIA LTD.

**56, EPIP, Phase-I Jharmajri, Baddi,
Distt. Solan (H.P.), 173205 INDIA**

Symptoms: Nausea, vomiting, tinnitus, hyperventilation, high fever, confusion, dehydration, disorientation, dizziness, coma and/or convulsions are common. Gastrointestinal haemorrhage is frequent. Some degree of acid-base disturbance is present in most cases.

Dealing with overdose in the event of accidental ingestion of product:

Serum salicylate levels above 3.6 mmol/l in adults (2.2 mmol/l in children) are likely to be toxic and levels of 5.4 mmol/l or above are fatal.

Treatment: Drug absorption can be stopped by induced vomiting or gastric lavage within an hour of ingestion. Activated charcoal is to be given by mouth if the patient is suspected of ingesting more than 120mg/kg of salicylate within 1 hour of presentation to enhance excretion.

The plasma salicylate concentration should be measured if ingestion of more than 12mg/kg of salicylate is suspected.

Elimination is increased by urinary alkalinisation, which is achieved by the administration of 1.26% sodium bicarbonate. The urinary pH should also be monitored.

Haemodialysis may be used for severe poisoning in patients with plasma salicylate concentrations >700mg/L or in patients with severe clinical or metabolic symptoms. Vulnerable patients such as children or the elderly may require dialysis at an earlier stage.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacological Group: Salicylic acid and derivatives

ATC code: N02BA03

Choline salicylate is the choline salt of salicylic acid and its pharmacology is essentially that of salicylic acid. It has exhibited anti-inflammatory analgesic and antipyretic actions in animal models, and is taken orally or is applied topically in man for the relief of pain and inflammation. Like salicylic acid, it has no antithrombotic activity and shows a low potential for production of gastrointestinal injury when given by the oral route. The pharmacological actions of choline salicylate are thought to be primarily mediated through inhibition of prostaglandin production, although effects on leukotriene pathways, kinin release and nerve conduction have been proposed.

Lidocaine Hydrochloride is one of the most widely used local anaesthetics, producing more prompt, more intense, longer lasting and more extensive anaesthesia than does an equal concentration of procaine (Peak anaesthesia within 2-5 minutes). Local anaesthetics are drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They have good powers of penetration and their action is reversible. Their use is followed by complete recovery in nerve function with no evidence of structural damage to nerve fibres or cells.

5.2 Pharmacokinetic properties

Choline salicylate is absorbed from the gut and is likely to be absorbed across mucous membranes such as all buccal mucosa.

Metabolism of salicylic acid is by glycine and phenolic or acyl glucuronate conjugation with small amounts undergoing hydroxylation. The plasma half-life of salicylic acid is 2-4 hours. Both metabolites and a small amount of intact salicylic acid are excreted, mainly in the urine. Salicylic acid is highly (80-90%) protein



SCOTT-EDIL PHARMACIA LTD.

56, EPIP, Phase-I Jharmajri, Baddi,
Distt. Solan (H.P.), 173205 INDIA

bound and although it has a low apparent volume of distribution of around 0.151 l/kg it is widely distributed throughout extracellular water and most tissues.

Lidocaine is readily absorbed through mucous membranes. They exert their effects in the form of the non-ionised base. Lidocaine undergoes first-pass metabolism in the liver and bioavailability is low after administration by mouth. It is rapidly de-ethylated to the active metabolite monoethylglycinexylidide and then hydrolysed by amidases to various compounds, including glycineexylidide which has reduced activity but a longer elimination half-life. Less than 10% of a dose is excreted unchanged via the kidneys. The metabolic products are excreted in the urine.

5.3 Preclinical safety data

No preclinical findings of relevance to the prescriber have been reported.

6. Pharmaceutical particulars

6.1 List of excipients

Benzalkonium Chloride Solution	BP
Glycerin	USP
Sorbitol 70%(Non Crystalline)	BP
Saccharin Sodium	BP
Pan Flavour	IH
Sodium metabisulfite	BP
Carbomer 940	USP
Diethanolamine	BP
Bronopol	BP
Disodium Edetate	BP
Purified water	BP

6.2 Incompatibilities

None known

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store in a cool dry and dark place. Do not allow to freeze.

6.5 Nature and contents of container

10 g Tube is packed in a carton along with a leaflet. Such 24 cartons are packed in outer carton.

6.6 Special precautions for disposal and other handling

None



SCOTT-EDIL PHARMACIA LTD.

**56, EPIP, Phase-I Jharmajri, Baddi,
Distt. Solan (H.P.), 173205 INDIA**

7. Manufactured By

Scott-Edil Pharmacia Limited,

56, EPIP, Phase-I, Jharmajri, Baddi, Distt. Solan- 173205 (H.P) INDIA

8. Marketed By

M/s Mankind Life-sciences.

9. Date of revision of the text

10/2021

10. DOSIMETRY (IF APPLICABLE)

Not applicable

11. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)

Not Applicable